U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula 2CH5N3.CH2O3
Molecular Weight 180.1658
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GUANIDINE CARBONATE

SMILES

NC(N)=N.NC(N)=N.OC(O)=O

InChI

InChIKey=STIAPHVBRDNOAJ-UHFFFAOYSA-N
InChI=1S/2CH5N3.CH2O3/c3*2-1(3)4/h2*(H5,2,3,4);(H2,2,3,4)

HIDE SMILES / InChI

Molecular Formula CH2O3
Molecular Weight 62.0248
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CH5N3
Molecular Weight 59.0705
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.

CNS Activity

Curator's Comment: The study was performed on rats.

Originator

Curator's Comment: Original article: A. Strecker, Liebigs Ann. Chem. 1861, 118, 151-177.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
GUANIDINE HYDROCHLORIDE

Approved Use

Guanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis.

Launch Date

1939
PubMed

PubMed

TitleDatePubMed
Presynaptic imidazoline receptors. New developments in characterization and classification.
1999 Jun 21
[The study of the Ca2+ role in cytotoxic response of human cells in culture to the action of xenobiotics].
2000
The picornavirus replication inhibitors HBB and guanidine in the echovirus-9 system: the significance of viral protein 2C.
2000 Apr
The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty.
2001
Topological diversity of artificial beta-barrels in water.
2001
Dihydrofolate reductase from Thermotoga maritima.
2001
Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents. 1. Conversion of 5-substituent on oxazolidinone.
2001 Apr
Total chemical synthesis of human matrix Gla protein.
2001 Apr
Strain-specified relative conformational stability of the scrapie prion protein.
2001 Apr
The structure of human mitochondrial branched-chain aminotransferase.
2001 Apr
High-sensitivity fluorescence anisotropy detection of protein-folding events: application to alpha-lactalbumin.
2001 Apr
Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent.
2001 Apr 12
Species-specific PCR for the identification of ovine, porcine and chicken species in meta and bone meal (MBM).
2001 Feb
Metric engineering of soft molecular host frameworks.
2001 Feb
[Discovery of cis-preference of aromatic N-methylamides and its application to molecular constructions].
2001 Feb
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor.
2001 Feb
Uremic concentrations of guanidino compounds inhibit neutrophil superoxide production.
2001 Feb
Endogenous guanidino compounds as uremic neurotoxins.
2001 Feb
Molecular specificities of antibodies against ovine and murine recombinant prion proteins.
2001 Feb 16
Collision-induced dissociation of ring-opened cyclic depsipeptides with a guanidino group by electrospray ionization/ion trap mass spectrometry.
2001 Jan
Dichlorobis(glycocyamine-O)copper(II).
2001 Jan
Detection of enterovirus and hepatitis A virus RNA in mussels (Mytilus spp.) by reverse transcriptase-polymerase chain reaction.
2001 Jan
The relationship between visible intracellular aggregates that appear after overexpression of Sup35 and the yeast prion-like elements [PSI(+)] and [PIN(+)].
2001 Jan
Folding-unfolding of goat alpha-lactalbumin studied by stopped-flow circular dichroism and molecular dynamics simulations.
2001 Jan 1
Disulfide-dependent folding and export of Escherichia coli DsbC.
2001 Jan 12
Conformational origin of the aggregation of recombinant human factor VIII.
2001 Jan 16
The PD...(D/E)XK motif in restriction enzymes: a link between function and conformation.
2001 Jan 16
A kinetic folding intermediate probed by native state hydrogen exchange.
2001 Jan 19
Engineering conformational flexibility in the lactose permease of Escherichia coli: use of glycine-scanning mutagenesis to rescue mutant Glu325-->Asp.
2001 Jan 23
Distributions of intramolecular distances in the reduced and denatured states of bovine pancreatic ribonuclease A. Folding initiation structures in the C-terminal portions of the reduced protein.
2001 Jan 9
[Antibody avidity: use for the diagnosis of HIV early infection].
2001 Jan-Feb
A rigid linker-scaffold for solid-phase synthesis of dimeric pharmacophores.
2001 Jan-Feb
Protein compactness measured by fluorescence resonance energy transfer. Human carbonic anhydrase ii is considerably expanded by the interaction of GroEL.
2001 Jun 15
alpha Arg-237 in Methylophilus methylotrophus (sp. W3A1) electron-transferring flavoprotein affords approximately 200-millivolt stabilization of the FAD anionic semiquinone and a kinetic block on full reduction to the dihydroquinone.
2001 Jun 8
Elucidation of a [4Fe-4S] cluster degradation pathway: rapid kinetic studies of the degradation of Chromatium vinosum HiPIP.
2001 Mar
Characterization of carbonic anhydrase from Neisseria gonorrhoeae.
2001 Mar
Cutinase unfolding and stabilization by trehalose and mannosylglycerate.
2001 Mar 1
The synthesis of beta-peptides containing guanidino groups.
2001 Mar 12
Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic.
2001 Mar 15
The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin.
2001 Mar 15
Structural alterations and inhibition of unisite and multisite ATP hydrolysis in soluble mitochondrial F1 by guanidinium chloride.
2001 Mar 20
Probing local conformational changes during equilibrium unfolding of firefly luciferase: fluorescence and circular dichroism studies of single tryptophan mutants.
2001 Mar 23
Dramatic stabilization of an SH3 domain by a single substitution: roles of the folded and unfolded states.
2001 Mar 30
The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain.
2001 Mar 30
The structure of denatured alpha-lactalbumin elucidated by the technique of disulfide scrambling: fractionation of conformational isomers of alpha-lactalbumin.
2001 Mar 30
Cofactor-induced refolding: refolding of molten globule carbonic anhydrase induced by Zn(II) and Co(II).
2001 Mar 6
Osmolytes protect mitochondrial F(0)F(1)-ATPase complex against pressure inactivation.
2001 Mar 9
The dimerization of folded monomers of ribulose 1,5-bisphosphate carboxylase/oxygenase.
2001 Mar 9
Proton and metal ion-dependent assembly of a model diiron protein.
2001 May
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.
2001 May 15
Patents

Sample Use Guides

Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.
Route of Administration: Oral
In Vitro Use Guide
Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:58:58 GMT 2025
Edited
by admin
on Mon Mar 31 19:58:58 GMT 2025
Record UNII
V3394X3G2W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NSC-2171
Preferred Name English
GUANIDINE CARBONATE
INCI  
INCI  
Official Name English
CARBONIC ACID, COMPD. WITH GUANIDINE (1:2)
Common Name English
DIGUANIDINIUM CARBONATE
Systematic Name English
GUANIDINE CARBONATE (2:1)
Systematic Name English
BISGUANIDINIUM CARBONATE
Systematic Name English
GUANIDINIUM CARBONATE
Systematic Name English
Code System Code Type Description
ECHA (EC/EINECS)
209-813-7
Created by admin on Mon Mar 31 19:58:58 GMT 2025 , Edited by admin on Mon Mar 31 19:58:58 GMT 2025
PRIMARY
PUBCHEM
11650
Created by admin on Mon Mar 31 19:58:58 GMT 2025 , Edited by admin on Mon Mar 31 19:58:58 GMT 2025
PRIMARY
CAS
593-85-1
Created by admin on Mon Mar 31 19:58:58 GMT 2025 , Edited by admin on Mon Mar 31 19:58:58 GMT 2025
PRIMARY
EPA CompTox
DTXSID0029189
Created by admin on Mon Mar 31 19:58:58 GMT 2025 , Edited by admin on Mon Mar 31 19:58:58 GMT 2025
PRIMARY
NSC
2171
Created by admin on Mon Mar 31 19:58:58 GMT 2025 , Edited by admin on Mon Mar 31 19:58:58 GMT 2025
PRIMARY
SMS_ID
300000041869
Created by admin on Mon Mar 31 19:58:58 GMT 2025 , Edited by admin on Mon Mar 31 19:58:58 GMT 2025
PRIMARY
FDA UNII
V3394X3G2W
Created by admin on Mon Mar 31 19:58:58 GMT 2025 , Edited by admin on Mon Mar 31 19:58:58 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY